uniQure N.V — Quarterly Cash Flow (NASDAQ:QURE) | MetaTrader

Open full chart

Financials

Overview 明細書 Statistics Dividends

Quarterly Annual

Total assets 645.81 M556.54 M605.4 M584.89 M888.38 M Total liabilities 589.99 M563.29 M571.72 M588.89 M659.64 M Total equity 55.82 M6.75 M33.69 M4 M228.75 M Total liabilities & shareholders' equities 645.81 M556.54 M605.4 M584.89 M888.38 M Total debt ————— Net debt —————

uniQure N.V

uniQure is a Dutch biopharmaceutical company which makes gene therapies. It has developed several adeno-associated virus gene therapies.

ニュース

uniQure: Shares Tumble On Fresh FDA Controversy - What Investors Should Know (NASDAQ:QURE)

AMT-130の規制経路が迫る中、uniQureの決算に注目集まる

uniQure earnings in focus as AMT-130 regulatory path looms

FDA長官の発言を受けてスティフェルがuniQure株についてコメント

Stifel comments on uniQure shares after FDA commissioner remarks

Uniqure Plummets As FDA's Marty Makary Disparages Rejected Rare Disease Drug

Applied Materials, Broadcom among market cap stock movers on Thursday

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Beats Revenue Estimates

UniQureの株価がFDAの遺伝子治療試験に関するコメントで急落

UniQure stock tumbles on FDA comments about gene therapy trial

Wolfe Researchが uniQure株をPeerperformでカバレッジ開始

uniQure stock initiated at Peerperform by Wolfe Research